Transcript Highlights:

• that the xylazine that is found in the Commonwealth's illicit drug supply is most often a non-pharmaceutical-grade
• compound that is not regulated by the FDA.
• It is... ...grade compound that is not regulated by the FDA.
• And I certainly think that pharmaceutical providers might fall in that category of an audience that the
• To Commissioner Gates' point, this may be something that also extends to pharmaceutical providers and

Keywords: 1212, all

Summary: The special commission on xylazine met virtually, called to order by House Chair Mindy Domb, with a quorum present. The commission approved the minutes from its December 11 public meeting and then reviewed the first draft of its final report, which is due to the Legislature by March 30, 2026. Staff explained the report structure, including a commission overview, findings and recommendations from each working group, and appendices with meeting materials and public resources. Commissioners discussed the distinction between licit veterinary xylazine and illicit xylazine in the drug supply, noting that the illicit supply is generally not diverted from legal veterinary sources but obtained through online vendors, and they clarified that xylazine is already classified in Massachusetts as a Schedule 6 substance, so the policy question is whether additional scheduling or penalties are warranted. For the best practices and enforcement section, staff recommended stronger guidance on secure storage and recordkeeping for authorized users, better reporting of diversion, theft, and suspicious orders, and focused enforcement on illicit production and fentanyl trafficking rather than individual possession. Commissioners suggested adding coordination among public safety, law enforcement, and the Attorney General’s office, as well as a state-level approach to emerging drug threats. In the outreach and treatment section, the draft emphasized that existing harm reduction, wound care, naloxone, and mobile outreach programs are effective but need broader coordination, more trauma-informed care, and better education for providers and first responders. Commissioners raised concerns about provider familiarity with xylazine, the need for first responders to include fire personnel and EMS, and the importance of not turning away people with xylazine-related wounds from recovery or treatment settings. The education and training section identified four target audiences: first responders, clinicians, non-clinicians in treatment and outreach settings, and people who use drugs and their families. The draft recommended tailored, stigma-free training and educational materials for each group, with consistent updates, continuing education credits where appropriate, and better access to centralized, real-time data on xylazine and other emerging contaminants. Commissioners discussed the need for centralized reporting and public health surveillance, including existing tools like the BSAS dashboard and StreetCheck, and several members urged the commission to recommend a DPH task force or similar body to monitor future drug supply threats. The meeting ended with staff outlining next steps: a revised draft would be circulated by the end of the week, feedback would be incorporated into a second draft by March 2, and the commission planned to vote on the final report at its March 9 meeting, with a backup meeting later in March if needed.

Transcript Highlights:

• Senate File 3783 will remove flavoring from the definition of compounding medicine.
• pharmacies could add flavor compounding pharmacies could add flavor to<01:08:09.920><c> medication</
• I'm here to support Senate File 3743, which clarifies the definition of compounding does not include
• </c><01:10:40.040><c> does</c><01:10:40.240><c> not</c> definition of compounding does not definition
• </c> agencies that regulate pharmaceutical agencies that regulate pharmaceutical waste<01:24:42.000><

Keywords: 1187, senate, all

Transcript Highlights:

• I now work for B-Bron Medical, a leading medical device and generic pharmaceutical company.
• I was not able or willing to rely on pharmaceuticals, and kratom gave me a safe and effective way to
• Banning the natural leaf while acknowledging that synthetic compounds, lack of education, and proper
• It is because of kratom's ability to take the place of high-profit pharmaceuticals and be used as an
• It's so beneficial that it cuts into the profits of the pharmaceutical companies who heavily lobby and

Keywords: 995, all

Summary: The Joint Committee on Public Health held a lengthy hearing to take testimony on a wide range of bills related to environmental health, PFAS, medical device chemicals, food access, lead poisoning, air quality, oral health, and school food additives. Chair Driscoll and Chair Decker emphasized that the hearing was for testimony only, no decisions would be made that day, and that written testimony could still be submitted. They also noted the high volume of speakers and asked witnesses to keep remarks brief. A major portion of the hearing focused on PFAS-related legislation, including bills to restrict PFAS in products and food packaging and to create a PFAS remediation trust fund. Municipal officials and advocates described the high costs of PFAS cleanup, especially for drinking water systems, citing Easton’s multimillion-dollar treatment investments and rate increases. Testimony from legislators and advocates argued that Massachusetts should act despite federal uncertainty, and that the state should stop PFAS at the source rather than leaving municipalities and residents to pay for remediation. The committee also heard strong support for a bill banning DEHP in medical devices, with physicians, nurses, and a bill sponsor saying the chemical can leach from IV bags and tubing and that safer alternatives already exist. The committee also heard testimony on bills to establish statewide food truck permitting, with food truck owners and a senator describing the current system as costly, duplicative, and inconsistent across municipalities. Another set of witnesses supported the “Bean New Deal,” which would expand plant-based food options in public institutions, senior nutrition programs, and WIC, citing health, equity, and cost savings. On lead poisoning, housing advocates and a representative backed bills to expand lead-safe housing requirements to all rental units, arguing the current law contributes to discrimination against families with children and leaves too much pre-1978 housing uncertified. The committee also heard support for an outdoor air pollution bill that would create an advisory committee, identify pollution hotspots, expand monitoring, and set reduction targets, with testimony from environmental justice groups, pediatricians, and legislators describing disproportionate asthma and other health harms in overburdened communities. Later testimony addressed oral health bills to create dental therapists and allow dental hygienists to administer nitrous oxide, with supporters saying the measures would expand access, reduce costs, and help underserved patients. The committee also heard testimony on a bill to prohibit harmful food dyes in competitive school foods, with parents describing behavioral and health concerns tied to synthetic dyes. No votes or formal actions were taken during the hearing.

Transcript Highlights:

• This is what uncertainty looks like on the ground, and ongoing federal instability compounds existing
• I wish we had the ability to set the spending targets on pharmaceutical drugs.
• These pressures are compounded by the impacts community safety net providers are facing.
• The fourth point is that the pharmaceutical cost of pharmaceuticals and prescription drugs needs to be
• The fourth point is the pharmaceutical, the cost of pharmaceuticals and prescription drugs needs to be

Keywords: 987, senate, all

Transcript Highlights:

• When you flush pharmaceuticals down the toilet, when you flush Drano down the toilet, all of this ends
• And also for pharmaceuticals and byproducts, or is that not currently being done? No, ma'am.
• or PFOS or... ...a plant of pharmaceuticals or PFOS or heavy metals.
• I think the standards are weak from EPA on all the metals and the pharmaceuticals, and we don't have
• As I mentioned previously, I've real concerns about the pharmaceutical products and their metabolites

Bills: HB3005, HB3007, HB3403, HB1907, HB3175, HB3986, HB3466, HB3411, HB4246

Keywords: climatology, emergency declaration, Oklahoma Climatological Survey, environment, weather data, public policy, state governance, natural resources, advisory councils, sunset law, water quality, hazardous waste, solid waste, radiation management, public health, biosolids, land application, environmental quality, agriculture, wastewater treatment

Summary: The committee took up several measures dealing with environmental regulation, waste management, and energy. Early on, it passed sunset-extension bills for the Oklahoma Climatological Survey and several environmental advisory councils. It then heard extensive debate on HB 1907, the Battery Stewardship Act, which would create a battery recycling system for small and medium batteries through DEQ. Supporters argued it would reduce landfill and garbage-truck fires, protect the environment, and create recycling value, while opponents raised concerns about added regulation, costs shifted to producers and retailers, and the creation of a new state FTE. Despite those objections, the bill passed 8-3. The committee also considered HB 3403, a pilot study on biosolids and sewage sludge applied to farmland. Members debated a committee substitute that shortened the study timeline from five years to three years and added a phased rollback of land application. Supporters said the study was needed because of unresolved questions about PFOS, pharmaceuticals, heavy metals, and other contaminants, while critics argued the timelines conflicted and the bill could be hard to implement. The committee substitute was adopted, an amendment to delete key rollback provisions failed, and the bill ultimately passed 8-2 after testimony from Oklahoma City utilities officials and multiple rounds of questions about testing, health risks, and disposal practices. The committee then passed HB 3175 to establish the Oklahoma Advanced Nuclear Energy Office, with members noting it would have minimal fiscal impact and could help Oklahoma build nuclear expertise and jobs. It also passed HB 3986, expanding a gross production tax exemption for wells completed with recycled water, and HB 3466, which removes the statutory requirement that the Corporation Commission maintain a petty cash fund. Finally, HB 3411, another biosolids-related bill to buy testing equipment and provide information to landowners, and HB 4246, a rural water transparency/lowest-bid bill, both passed unanimously or near-unanimously. The meeting ended with the chair thanking members and adjourning.

Transcript Highlights:

• This problem is going to only compound on itself, especially in rural communities, and in communities
• Every compound we rule out brings us closer to one that works for patients, so getting to know as quickly
• With respect to pharmaceutical research, the FDA remains the gold standard for regulation.
• So when a U.S. pharmaceutical company begins developing a new drug, the synthetic DNA that's at the core
• So that's a part of the pharmaceutical supply chain that is one of the places where the United States

Summary: The hearing focused on how artificial intelligence is being used across California’s life sciences sector, from digital health and medical devices to cancer research, drug discovery, and biosecurity. The chairs emphasized California’s economic leadership in biotechnology and the need to balance innovation with privacy, consumer protection, and equitable access. Members also raised concerns about whether the state can preserve its research and manufacturing ecosystem, and about the role of public infrastructure such as CalCompute, open-source tools, and state procurement in supporting innovation. The first panel featured representatives from UCSF, the Parker Institute for Cancer Immunotherapy, and Lawrence Livermore National Laboratory. They described AI applications in remote blood pressure monitoring, wearable and sensor-based health data, cancer drug discovery, learning from every patient, clinical trial matching, and public health surveillance. Witnesses stressed that AI can speed discovery and improve care, but only if data can move across systems, models are validated, and privacy safeguards are strong. They also warned that innovation could be hollowed out if compute, data access, and translational funding are not supported in California. Committee members asked about HIPAA and CMIA protections, interoperability with Epic, validation of AI tools, FDA regulation, and whether proprietary models limit independent evaluation. Witnesses said consumer sensor data often falls outside HIPAA, that FHIR and other interoperability standards already exist, and that open-source layers could sit on top of existing EHR systems. They also discussed the need for ongoing post-market monitoring, human oversight, and faster regulatory pathways, especially for AI-enabled diagnostics and personalized therapies. The second panel highlighted company use cases. Pangea Data described AI systems that identify care gaps in chronic, rare, and oncology conditions and argued for better reimbursement frameworks so rural and smaller providers can adopt them. Dexcom explained how it uses AI in its continuous glucose monitoring products, with strong FDA-backed verification, validation, cybersecurity controls, and guardrails to prevent unsafe advice. Lilly Ventures discussed AI in drug discovery and the need to modernize development pipelines, while Twist Bioscience was introduced as another company working on AI-driven life science innovation.

Transcript Highlights:

• Financial sanctions compound that disparity and can function as an early driver of deeper system involvement
• Tonya Neal, Pharmaceutical Care Management. Are you present, Tonya? Please proceed. Hello.
• I'm the senior director for state affairs for the Pharmaceutical Care Management Trade Association.
• Tonya Neal, Pharmaceutical Care Management. Are you present, Tonya? Please proceed. Hello.
• I'm the senior director for state affairs for the Pharmaceutical Care Management Trade Association.

Keywords: 912, senate, all

Summary: The Health and Human Services committee hearing opened with notice that the meeting was being streamed and could reconvene later if technical problems forced an abrupt end. The chair also announced a one-minute testimony limit and proceeded through several bills, taking mostly written and oral support testimony and asking limited questions. No votes were taken in the portion provided. HB 1626, relating to youth penalties, drew strong support from the Office of Hawaiian Affairs, youth advocates, the ACLU, the Department of Education, and others. Testifiers said financial sanctions on youth are ineffective, disproportionately burden Native Hawaiian youth, and function as poverty penalties; they urged replacing fines with community service, restorative practices, and ʻāina-based programs, and eliminating uncollectible legacy debt. The chair moved on after no member questions. HB 1643, relating to pharmacy, was discussed with support from the Hawaii Pharmacists Association, Kaiser, the Board of Pharmacy, independent pharmacies, and PBM representatives. Testimony focused on amendment language, audit procedures, HIPAA concerns, and the need for flexibility for small island pharmacies. HB 1668, relating to Medicaid, received broad support from disability advocates and the Department of Human Services; witnesses said CMS had already approved the underlying state plan amendment removing income and asset limits for certain workers with disabilities, but they wanted the protection codified in law to preserve it long term. The chair asked whether codification was necessary and was told it would not be harmful and would help ensure continuity if federal policy changed. The committee then heard HB 1550 on drug paraphernalia and syringe access, with support from Shipta and the Department of Health; testimony emphasized preserving flexibility for the statewide syringe access program to respond to emerging drugs like xylazine. HB 1974, relating to health, was presented as a planning measure for hearing loss; testifiers said Hawaii lacks a comprehensive hearing-loss plan and that the bill would fund a state planning process, not direct services. HB 1858 on vital statistics drew support from clinicians and medical organizations, who said better data on spontaneous fetal deaths is needed and that the term used in the bill is standard medical and CDC terminology. HB 1871 and HB 1966 also received support, with HB 1966’s EMS special fund prompting discussion about the cigarette-tax revenue source; the chair questioned the nexus to EMS, and the Department of Health said the revenue currently funds the special fund and there is no alternative funding stream.

Bills: HB 1106, HB 3284, HB 541, HB 713, HB 1403, HB 1586, HB 1942, HB 2070, HB 2844, HB 2851, HB 3151, HB 3749, HB 3940, HB 3963, HB 4454, HB 4466, HB 4795, HB 5154, HB 5394, SB 1357, HB 1052, HB 4099, HB 4638, HB 5147

Keywords: child abuse, neglect, gender identity, sexual orientation, child welfare, marriage, family, Texas Commission, family welfare, marriage support, stability, premarital education, child development, strong families, direct patient care, healthcare, physicians, medical services, insurance regulation, maternal health

Bills: HB 1106, HB 3284, HB 541, HB 713, HB 1403, HB 1586, HB 1942, HB 2070, HB 2844, HB 2851, HB 3151, HB 3749, HB 3940, HB 3963, HB 4454, HB 4466, HB 4795, HB 5154, HB 5394, SB 1357, HB 1052, HB 4099, HB 4638, HB 5147

Keywords: child abuse, neglect, gender identity, sexual orientation, child welfare, marriage, family, Texas Commission, family welfare, marriage support, stability, premarital education, child development, strong families, direct patient care, healthcare, physicians, medical services, insurance regulation, maternal health

Transcript Highlights:

• But my next part of that would be what pharmaceutical coverage is...

Bills: HB1464, HB1635, HB2516, HB3317, HB3502, HB4012, HB4268, HB4386, HB4877, SB916

Keywords: prescription drugs, drug pricing, pharmacy benefits, health insurance, health benefit plan, insurer, HMO, self-insured employer, public employer, school district, county, municipality, university system, higher education, retirees, dependent coverage, stop-loss coverage, bulk purchasing, group purchasing, purchasing pool

Transcript Highlights:

• We urge caution before advancing any mandates that could compound the affordability crisis already underway
• We urge caution before advancing any mandates that could compound the affordability crisis already underway
• many health care providers can purchase it through their own vendor agreements with their own pharmaceutical
• relationships with every health care insurance company in the United States, 18 of the top 20 pharmaceutical
• companies, and in 2023, they partnered with TransUnion to enable pharmaceutical advertisers to target

Summary: The committee heard testimony on three health care bills. HB 1496 would cap charges for electronically stored medical records at $50 for patients and certain authorized recipients, while removing a free-copy provision tied to SSI/SSDI appeals and changing attorney fee language to “prevailing patient.” Supporters, including patient advocates, attorneys, and injured workers, said current record fees can reach thousands of dollars and block access to justice; opponents, including hospitals, home care providers, and records vendors, argued the bill would not cover the labor and HIPAA compliance work involved in large third-party requests and could shift costs to providers and patients. The bill remained in hearing with testimony continuing after the committee moved through other bills. HB 2182 would change how the Department of Corrections distributes its stockpile of mifepristone and misoprostol, removing the requirement that the medications be sold at cost plus a $5 fee and instead allowing, but not requiring, payment while directing DOC and the Department of Health to coordinate distribution to providers and facilities. The prime sponsor and supporters said the bill is needed so the state’s stockpile does not go unused or expire and to remove barriers to access for abortion and miscarriage care; opponents argued the bill subsidizes abortion, raises legal and taxpayer concerns, and should be rejected. Public testimony on HB 2182 was closed after hearing from both supporters and opponents. HB 2196 would require certain fully insured health plans to cover IVIG for PANS and PANDAS, with initial and medically necessary follow-up courses, and would bar denials based on prior treatment, age, out-of-state care when unavailable in Washington, or treatment guidelines that only address psychiatric symptoms. The sponsor, families, and physicians described severe, sudden-onset symptoms in children and said IVIG can be life-changing after other treatments fail, while insurers warned the mandate could add to already rising premiums and noted the treatment can be very expensive. HB 2242 would shift vaccine and preventive-service recommendation authority from federal bodies to the Department of Health, while preserving no-cost coverage for preventive services and updating the reference date for protected services; the governor, insurance commissioner, public health officials, and many physicians supported it as a way to preserve access amid federal instability and rising vaccine-preventable disease, while questions focused on whether the bill would change school or daycare requirements, which staff said it would not.

Transcript Highlights:

• As prime contractors are liable for subcontractor compliance, this risk compounds.
• happy to be here to present SB 1185, which applies skilled and trained workforce standards to pharmaceutical
• Pharmaceutical facilities are among the most technically complex construction environments in the modern
• failures, workforce deficiencies, catastrophic incidents, or public safety concerns associated with pharmaceutical
• all future construction, alteration, repair, installation, demolition, and maintenance work at pharmaceutical

Summary: The Assembly Labor and Employment Committee heard several bills focused on worker protections, AI in the workplace, bereavement leave, and construction labor standards. SB 909 by Senator Smallwood-Cuevas would increase public works contractor registration fees, raise prevailing wage and related penalties, and direct half of collected penalties back into the Public Works Enforcement Fund. Supporters said the bill would help combat wage theft and misclassification and strengthen enforcement; opponents argued the higher fees and penalties would burden contractors without fixing enforcement backlogs. The committee voted the bill out on a due pass motion to Appropriations. The committee also approved SB 951 by Senator Reyes, which would require 60-day notice when 25 or more workers are displaced by technology and require reporting on AI-related job impacts. Supporters framed it as a response to rapid AI-driven layoffs and a way to gather real-time data; opponents raised concerns about small employers, proprietary information, and litigation. SB 947 by Senator McNerney, the “No Robo Bosses Act,” would require human review of automated discipline, termination, or deactivation decisions and restrict predictive behavior analysis. Supporters said it would prevent biased or mistaken automated decisions; opponents objected to the inclusion of independent contractors, private rights of action, and other provisions. Both bills were advanced to the Committee on Privacy and Consumer Protection. The committee also passed SB 1149 by Senator Durazo, which would expand bereavement leave to cover a “designated person,” including chosen family relationships. Supporters, including AARP and a witness who described losing a long-term partner, said the bill reflects modern family structures; there was no opposition. In addition, SB 1185 by Senator Cortese, applying skilled and trained workforce standards to pharmaceutical facility construction, was approved despite opposition from business and construction groups who said there was no demonstrated safety problem and that the mandate could raise costs and reduce competition. Several other bills on the consent calendar were also approved, and all measures were reported out of committee.

Transcript Highlights:

• I would say in my 44 years in the pharmaceutical, medical device, and biotech industry, I would also
• </c> in my 44 years in the pharmaceutical in my 44 years in the pharmaceutical medical<00:04:39.240><
• </c> uh, belatedly that pharmaceutical uh, belatedly that pharmaceutical companies<00:05:52.560><c> have
• </c> compounding under the chapter. compounding under the chapter.
• ><c> the</c> Compounding is regulated under the Compounding is regulated under the United<00:55:04.000

Keywords: 1191, senate, all

Transcript Highlights:

• THC was a gateway to pharmaceutical medicines.
• This is about the pharmaceutical lobby. This is about the alcohol lobby.
• So it's just not keeping people off pharmaceuticals to use these products.
• It's putting them on pharmaceuticals, eventually if they have a brain break.
• These are different compounds.

Bills: SB 5, SB 11, SB 12

Keywords: disaster relief, flood preparedness, emergency funding, local government support, meteorological forecasting, human trafficking, trafficking victim, compelling prostitution, affirmative defense, criminal defense, coercion, force fraud or coercion, sexual exploitation, victim protection, Penal Code, Texas criminal law, prosecution, party liability, affirmative defense statute, survivor rights

Summary: The Senate Committee on State Affairs took up Senate Bill 5, which Senator Perry described as a ban on intoxicating THC consumer products while preserving legal CBD, CBG, hemp seed, hemp seed protein powder, and hemp seed oil products. Perry argued that most retail THC products are already illegal under federal law, that the industry has used loopholes and misleading labeling to sell high-potency products, and that regulation would be ineffective because chemists can quickly alter formulations. He also said the bill would steer people with medical needs toward the Texas Compassionate Use Program (T-Cup), which he and other supporters described as the proper physician-guided alternative. Committee members and witnesses repeatedly discussed the distinction between legal hemp-derived products and intoxicating THC products, and Perry said the bill would not touch non-consumable hemp uses such as fiber and clothing. Invited testimony came from law enforcement and medical witnesses who supported the bill. Texas Police Chiefs Association representative Steve Dye, Kaufman County District Attorney Early Wiley, and Chambers County Sheriff Brian Hawthorne all said regulation would be too costly, too complex, and ultimately unenforceable, while a ban would be clearer and easier to enforce. They cited overloaded DPS labs, the need for expensive private testing, limited police and prosecutor resources, and the difficulty of keeping up with constantly changing cannabinoids and out-of-state products. Hawthorne and Wiley described raids and investigations involving warehouses, retail stores, cash seizures, and products they said were marketed to young people and often mislabeled or imported from other states. They also said the bill would help law enforcement by creating a clearer legal line and protecting legitimate CBD/CBG businesses. Dr. Lindy McGee, speaking for the Texas Medical Association and Texas Pediatric Society, testified that retail THC products pose serious risks to children and adolescents, including addiction, impaired brain development, psychosis, suicide attempts, self-harm, accidental toddler ingestions, and possible long-term cognitive effects. She said there is no effective medication treatment for THC addiction comparable to nicotine cessation tools, and she supported restrictions such as child-resistant packaging, no marketing to minors, and age limits, while opposing criminal penalties for possession by minors. Senators asked follow-up questions about brain development, memory, dementia risk, pregnancy, and cardiovascular effects. No vote was taken during the portion provided, and the committee continued with invited testimony and questions.

Transcript Highlights:

• Phil Christopherelli, with the Pharmaceutical Care Management Association, we are the nation's trade
• We negotiate rebates with pharmaceutical companies, we process drug claims, and we create network...
• Pharmaceutical companies, we process drug claims, and we create networks of pharmacies where you can
• Nick Waltz, Louisiana Compound Pharmacy Coalition, does not wish to speak and is in support.

Summary: The Senate Finance Committee met with eight members present and deferred HB 127. It then considered a series of bills, most of which were reported favorably without opposition. HB 22 revised COLA rules for the clerks of court retirement system, allowing more frequent COLAs when the system is better funded; HB 324 made judicial stipends permanent and added future COLAs subject to available funding; HB 233 increased jury mileage reimbursement; HB 47 reorganized assessor retirement COLA statutes; HB 533 allowed St. Tammany Parish to transfer unused witness-fee account balances to the 22nd Judicial District Court; HB 980 adjusted eligibility for the Firemen’s Supplemental Pay Board; HCR 45 urged Congress to clarify ARPA deadlines for water projects; HB 559 increased court costs in the 4th Judicial District; HB 290 recreated the Department of Treasury and related entities in statute; and HB 382 addressed Joint Legislative Committee on the Budget review authority over Group Benefits plans. The committee also reported HB 1157 favorably, creating a financing bank mechanism for infrastructure projects, and HB 575 favorably, giving youth aging out of foster care preferred access to surplus state vehicles through the Louisiana Property Assistance Agency. Several measures drew more discussion. HB 1236, dealing with pharmacy benefit managers and professional dispensing fees, prompted extensive testimony from the sponsor, the Legislative Fiscal Office, the Department of Insurance, independent pharmacies, and PBM representatives. Supporters said it clarifies and strengthens enforcement of existing PBM law and protects independent pharmacies; opponents argued the bill’s requirement that PBMs bear dispensing-fee costs would be difficult to implement and could raise premiums. The sponsor said he would work on amendments, including clarifying language and a delayed effective date, and the bill was nevertheless moved favorably. SB 25, on registrar of voters compensation, was amended to a revised pay structure and then reported favorably. HB 47 and HB 533 were also presented as funding and administrative cleanups for retirement and court-related accounts, with local support noted. The committee also heard HB 233 on jury duty mileage reimbursement, which the sponsor said updates a 1961 rate and would be funded locally at an estimated average increase of about $4,000 per judicial district. HB 324 on judicial salaries was described as self-funded by the judiciary and subject to available funding, with no budget impact. HB 575 on foster youth transportation was presented as a non-appropriation measure aimed at helping youth aging out of foster care by giving them preferred access to surplus vehicles. HB 382, which concerns the Joint Legislative Committee on the Budget’s role in approving Group Benefits plans, was reported favorably with little discussion. The meeting ended after a motion to adjourn.

Transcript Highlights:

• This is what uncertainty looks like on the ground, and ongoing federal instability compounds existing
• I wish we had the ability to set the spending targets on pharmaceutical drugs.
• These pressures are compounded by the impacts community safety net providers are facing.
• The fourth point is that the cost of pharmaceuticals and prescription drugs needs to be reined in.
• The fourth point is the pharmaceutical, the cost of pharmaceuticals and prescription drugs needs to be

Summary: The joint informational hearing of the Senate and Assembly Health Committees focused on the “cost of uncertainty” in health coverage, access, and affordability amid federal policy changes. Opening remarks from committee leaders and members emphasized that California’s gains under the Affordable Care Act and Health for All policies—high coverage rates, consumer protections, and lower uninsured rates—are now threatened by federal rollbacks, including the expiration of enhanced premium tax credits and H.R. 1. Members repeatedly cited rising premiums, skipped care, medical debt, and the risk of coverage losses, especially for low-income Californians, workers, seniors, and immigrant communities. The first panel featured federal policy and state implementation experts, including Don Joyce, Jessica Altman of Covered California, and Elizabeth Lansberg of HCAI’s Office of Health Care Affordability. Testimony described the ACA’s coverage expansions and the current federal threats: shorter open enrollment, more verification requirements, loss of enhanced subsidies, and changes affecting immigrants and preventive coverage. Covered California reported that average monthly premiums could nearly double without the subsidies, new enrollment is down sharply, and more consumers are shifting into bronze plans with higher deductibles. HCAI explained its affordability strategy through spending targets, consolidation review, and primary care investment, while members asked about the impact of federal cuts on provider taxes, uncompensated care, and whether California can sustain coverage without new revenue. The second panel, with UC Berkeley Labor Center’s Miranda Dietz and California Health Care Foundation’s Christoph Stremikis, broadened the discussion to statewide cost drivers and consumer impacts. They highlighted that more than half of Californians under 65 rely on job-based coverage, yet premiums, deductibles, and out-of-pocket costs have risen faster than wages. They also pointed to medical debt, administrative waste, market consolidation, and underinvestment in primary care as major drivers of unaffordability. Members asked about the 25% of health spending that does not improve patient care, the role of fraud versus administrative friction, the effect of cost growth targets on workers, and the need for preventive care and possible revenue solutions. The hearing then moved to a third panel on human impacts, beginning with testimony from a Central Valley promotora describing how families are choosing lower-tier coverage, struggling with diabetes care, and facing higher premiums after subsidy losses.

Transcript Highlights:

• This is what uncertainty looks like on the ground, and ongoing federal instability compounds existing
• I wish we had the ability to set the spending targets on pharmaceutical drugs.
• These pressures are compounded by the impacts community safety net providers are facing.
• The fourth point is that the cost of pharmaceuticals and prescription drugs needs to be reined in.
• The fourth point is the pharmaceutical, the cost of pharmaceuticals and prescription drugs needs to be

Keywords: 988, house, all

Transcript Highlights:

• It prohibits pharmaceutical manufacturers from unilaterally restricting where 340B-priced medications
• That represents a 20% year-over-year increase, and this program and its discounts with pharmaceutical
• I ask you to put the health of rural communities over the profits of big pharmaceutical companies and
• In closing, I urge you not to view a vote against this bill as a vote for pharmaceutical companies.
• Ann Murray with Bristol-Myers Squibb, a research-based pharmaceutical company committed to delivering

Summary: The Senate Health and Long-Term Care Committee held a hearing on several bills. SB 5904 would prohibit non-human entities from using nursing titles; the sponsor and nursing groups said it is meant to increase transparency around AI and ensure patients know when they are interacting with a real nurse. SB 5915 would change Health Technology Assessment Program review criteria and timelines, with supporters arguing it would better account for Medicare coverage and national guidelines, especially for rare and life-threatening conditions. SB 6025 would update the definition of fetal death to allow gestational age to be determined by the best clinically accurate method rather than last menstrual period, and medical professionals and the sponsor said this would reduce emotional, financial, and legal burdens on grieving families. SB 5933 would require near real-time sharing of overdose data into ODMAP; public health, local government, and recovery advocates said it would improve overdose response, while one witness asked that poison center data be included and clarified separately. SB 5990 would allow APRNs and physician assistants to serve as local health officers in counties under 100,000 population; rural county officials supported the added flexibility, while public health groups and naturopathic physicians raised concerns about qualifications and asked that naturopathic doctors be included as well. SB 5981 would restrict drug manufacturers from limiting 340B drug access through contract pharmacies or requiring data as a condition of discounts; safety-net hospitals, community health centers, pharmacies, and patients said it protects access and reinvestment in care, while manufacturers, employer groups, and industry representatives argued it increases costs, lacks transparency, and may not ensure savings reach patients. No votes or final committee actions were taken in the transcript; each bill was heard and testimony was closed. Sign-in counts were reported for several bills, including strong pro support for SB 5904, SB 5915, SB 5933, and SB 5981, and mixed or substantial opposition on SB 6025 and SB 5990.

Bills: SB6, SB7, SB8, SB11, SB12, SB13, SB15, SB 6, SB 7, SB 8, SB 11, SB 12, SB 13, SB 15, SB 17

Keywords: SB 6, Woman and Child Protection Act, abortion, abortion-inducing drugs, medication abortion, mifepristone, misoprostol, pro-life, pro-choice, Texas abortion law, civil liability, qui tam, private enforcement, bounty hunter law, attorney general, parens patriae, abortion litigation, anti-SLAPP, Texas Citizens Participation Act, fee shifting

Transcript Highlights:

• Senator Kavanaugh, can you speak a little bit more about the rebates on pharmaceuticals?
• When I met the advocates, the pharmaceutical folks.
• Browning, so you represent Otsuka, American Pharmaceutical.
• This is not some chemical compound.
• This is not some chemical compound.

Bills: SB1052, SB1115, SB1118, SB1120, SB1121, SB1124, SB1171, SB1172, SB1174, SB1175, SB1214, SB1233, SB1235, SB1316, SB1345, SB1372, SB1399, SB1458, SB1494, SB1496, SB1564, SB1602, SB1621, SB1628, SB1630, SB1631, SB1668, SB1672, SB1814, SB1821

Keywords: assisted living, health care, hyperbaric oxygen therapy, physician orders, informed consent, AHCCCS, remote work, state agency, employment, public health, housing, zoning, middle housing, urban development, duplexes, triplexes, fourplexes, townhomes, historic preservation, radiation protection